卵巢癌是临床最常见的妇科恶性肿瘤之一，其主要转移途径为腹腔转移，但其中所涉及的机制及相关分子机理目前尚未完全阐明。因此，筛选和鉴定介导卵巢癌腹腔转移关键分子并探索相关分子机理有助于发现卵巢癌新型早期诊断标志物及靶向治疗新策略。我们前期研究发现，CXCL14在人卵巢癌腹腔转移灶中的表达显著高于原位灶，其表达水平与卵巢癌患者临床预后密切关联，体外研究发现CXCL14能显著增强卵巢癌细胞的转移能力。本项目拟在此基础上以卵巢癌腹腔转移模型为研究对象，采用分子细胞学方法从体内外水平系统研究CXCL14在卵巢癌腹腔转移中的生物学功能，阐明其影响卵巢癌转移的相关分子机制，明确CXCL14作为卵巢癌早期诊断标志物或药物靶标的潜在应用价值，为发展新的卵巢癌诊断治疗策略提供理论依据。

Ovarian cancer is one of the most common gynecological malignancies, whose primary metastatic site is peritoneal cavity. However, the underlying molecular mechanisms remain far from elucidated. Thus, it is of great importance to screen for key mediators responsible for peritoneal metastasis of ovarian cancer, which could potentially serve as novel diagnostic biomarkers as well as therapeutic targets of ovarian cancer. We previously found that the expression level of CXCL14 in the metastatic site of ovarian cancer was significantly higher than that in the primary site, which was also correlated with clinical outcome of ovarian cancer patients. Moreover, in vitro studies demonstrated that CXCL14 overexpression could remarkably enhance the metastatic capacity of ovarian cancer cells. This project aims to use peritoneal metastatic ovarian cancer as experimental model to systematically analyze the biological functions of CXCL14 in ovarian cancer peritoneal metastasis by molecular and cellular biological techniques on both in vivo and in vitro levels. More importantly, we attempt to explore the underlying molecular mechanisms to elucidate the importance of CXCL14 in ovarian cancer metastasis as well as to clarify the potential application values of CXCL14 as a novel early diagnostic biomarker and therapeutic target for ovarian cancer, which might lay theoretical foundations for the development of new diagnosis and treatment strategies of ovarian cancer.